Top-News

Halozyme Therapeutics Aktie News

Aktie
WKN:  A0DLHS ISIN:  US40637H1095 US-Symbol:  HALO Branche:  Biotechnologie Land:  USA
54,58 €
+0,58 €
+1,07%
22:14:30 Uhr
Depot/Watchlist
Marktkapitalisierung *
7,67 Mrd. €
Streubesitz
-
KGV
13,94
neu: Nachhaltigkeits-Score
36 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,98: JU5J3D
Werbung

Halozyme Therapeutics News

04.12.25 - PR Newswire
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany PR Newswire
25.11.25 - PR Newswire
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference PR Newswire
18.11.25 - PR Newswire
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery PR Newswire
17.11.25 - PR Newswire
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab PR Newswire
07.11.25 - LYNX Analysen
Plattform statt Risiko: Halozyme auf dem Weg in die Zukunft?
Ausstieg aus der eigenen Forschung, Fokus auf Plattformtechnologie – Halozyme zeigt, wie kluges Strategie-​Management aussieht. Jetzt vollständige Analyse lesen
07.11.25 - PR Newswire
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma PR Newswire
06.11.25 - PR Newswire
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 PR ...
05.11.25 - PR Newswire
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 PR Newswire
04.11.25 - wallstreetONLINE Redaktion
Hebel-Idee | Long-Chance: Warum ausgerechnet auf Novo Nordisk setzen, wenn diese Aktie so viel besser ist?
Während viele Anlegerinnen und Anleger verzweifelt auf einen Turnarnound der Aktie von Novo Nordisk warten, hat Halozyme schon jetzt deutlich mehr zu bieten. Willkommen zum ...
03.11.25 - PR Newswire
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS PR Newswire
21.10.25 - PR Newswire
Halozyme to Report Third Quarter 2025 Financial and Operating Results
Halozyme to Report Third Quarter 2025 Financial and Operating Results PR Newswire
01.10.25 - PR Newswire
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s PR Newswire
28.08.25 - PR Newswire
Halozyme to Participate at Upcoming Investor Conferences
Halozyme to Participate at Upcoming Investor Conferences PR Newswire
06.08.25 - ARIVA.DE Redaktion
Dieses Biotech-Unternehmen schlägt Bayer, Evotec, Novo Nordisk & Co. um Längen!
Während Anlegerinnen und Anleger verzweifelt auf einen Turnaround der Aktien von Bayer, Evotec und Novo Nordisk warten, liefert dieser Rivale konstant Gewinne.
05.08.25 - PR Newswire
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS PR Newswire
23.07.25 - PR Newswire
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma PR Newswire
22.07.25 - PR Newswire
Halozyme to Report Second Quarter 2025 Financial and Operating Results
Halozyme to Report Second Quarter 2025 Financial and Operating Results PR Newswire
30.06.25 - PR Newswire
Halozyme Therapeutics Added to Russell 1000® Index
Halozyme Therapeutics Added to Russell 1000® Index PR Newswire
20.06.25 - PR Newswire
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating ...
28.05.25 - PR Newswire
Halozyme to Participate at Upcoming Investor Conferences
Halozyme to Participate at Upcoming Investor Conferences PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »